Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

E. Garon · SciRah

Researcher profile · Semantic Scholar

E. Garon

Share profile

E. Garon — researcher profile on SciRah

h-index: 71
Works: 500
Citations: 46K

Most-cited papers

Pembrolizumab Plus Pemetrexed and Platinum in Nonsquamous Non–Small-Cell Lung Cancer: 5-Year Outcomes From the Phase 3 KEYNOTE-189 Study
M. Garassino, S. Gadgeel, G. Speranza, E. Felip +17 more
2023Journal of Clinical Oncology632 citations Open access
Semantic Scholar
Durvalumab With or Without Tremelimumab in Combination With Chemotherapy as First-Line Therapy for Metastatic Non–Small-Cell Lung Cancer: The Phase III POSEIDON Study
M. Johnson, B. Cho, A. Luft, J. Alatorre-alexander +15 more
2022Journal of Clinical Oncology381 citations Open access
Semantic Scholar
Neoadjuvant atezolizumab for resectable non-small cell lung cancer: an open-label, single-arm phase II trial
J. Chaft, F. Oezkan, M. Kris, P. Bunn +32 more
2022Nature Medicine233 citations Open access
Semantic Scholar
Personalized neoantigen vaccine NEO-PV-01 with chemotherapy and anti-PD-1 as first-line treatment for non-squamous non-small cell lung cancer.
M. Awad, R. Govindan, Kristen N. Balogh, D. Spigel +20 more
2022Cancer Cell217 citations Open access
Semantic Scholar
First-in-Human, Phase I Dose-Escalation and Dose-Expansion Study of Trophoblast Cell-Surface Antigen 2–Directed Antibody-Drug Conjugate Datopotamab Deruxtecan in Non–Small-Cell Lung Cancer: TROPION-PanTumor01
T. Shimizu, Jacob M. Sands, K. Yoh, A. Spira +13 more
2023Journal of Clinical Oncology141 citations Open access
Semantic Scholar
Cost-effective methylome sequencing of cell-free DNA for accurately detecting and locating cancer
M. Stackpole, Wei-Hua Zeng, Shuo Li, Chun-Chi Liu +36 more
2022Nature Communications88 citations Open access
Semantic Scholar
Tumor Microenvironment
Tonya Walser, J. Yanagawa, E. Garon, J. Lee +1 more
2023Cancer treatment and research85 citations
Semantic Scholar
Bintrafusp alfa versus pembrolizumab in patients with treatment-naive, PD-L1-high advanced non-small cell lung cancer: a randomized, open-label, phase 3 trial.
B. Cho, J. S. Lee, Yi-Long Wu, I. Çiçin +21 more
2023Journal of Thoracic Oncology76 citations Open access
Semantic Scholar
Canakinumab as Adjuvant Therapy in Patients With Completely Resected Non–Small-Cell Lung Cancer: Results From the CANOPY-A Double-Blind, Randomized Clinical Trial
E. Garon, Shun Lu, Y. Goto, P. D. de Marchi +15 more
2023Journal of Clinical Oncology73 citations
Semantic Scholar
Comprehensive tissue deconvolution of cell-free DNA by deep learning for disease diagnosis and monitoring
Shuo Li, Wei-Hua Zeng, X. Ni, Qiao Liu +18 more
2023Proceedings of the National Academy of Sciences of the United States of America68 citations Open access
Semantic Scholar
Defining comprehensive biomarker‐related testing and treatment practices for advanced non‐small‐cell lung cancer: Results of a survey of U.S. oncologists
K. Mileham, Caroline Schenkel, S. Bruinooge, J. Freeman-Daily +12 more
2021Cancer Medicine53 citations Open access
Semantic Scholar
Associations of Tissue Tumor Mutational Burden and Mutational Status With Clinical Outcomes With Pembrolizumab Plus Chemotherapy Versus Chemotherapy For Metastatic NSCLC
M. Garassino, S. Gadgeel, S. Novello, B. Halmos +17 more
2022JTO Clinical and Research Reports47 citations Open access
Semantic Scholar
Safety profile of pembrolizumab monotherapy based on an aggregate safety evaluation of 8937 patients
J. Brahmer, Georgina V. Long, Omid Hamid, E. Garon +24 more
2024European Journal of Cancer46 citations Open access
Semantic Scholar
Biomarker-directed, pembrolizumab-based combination therapy in non-small cell lung cancer: phase 2 KEYNOTE-495/KeyImPaCT trial interim results
M. Gutierrez, Wei-Sen Lam, M. Hellmann, M. Gubens +20 more
2023Nature Medicine42 citations
Semantic Scholar
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lung cancer and mesothelioma
R. Govindan, C. Aggarwal, S. Antonia, M. Davies +18 more
2022Journal for ImmunoTherapy of Cancer39 citations Open access
Semantic Scholar
FP13.02 Pembrolizumab + Pemetrexed-Platinum vs Pemetrexed-Platinum for Metastatic NSCLC: 4-Year Follow-up From KEYNOTE-189
J. Gray, D. Rodríguez-Abreu, S. Powell, M. Hochmair +18 more
202136 citations Open access
Semantic Scholar
MRTX-500 Phase 2 Trial: Sitravatinib With Nivolumab in Patients With Nonsquamous NSCLC Progressing On or After Checkpoint Inhibitor Therapy or Chemotherapy
K. He, D. Berz, S. Gadgeel, W. Iams +16 more
2023Journal of Thoracic Oncology34 citations Open access
Semantic Scholar
CCL21-DC in situ vaccination in murine NSCLC overcomes resistance to immunotherapy and generates systemic tumor-specific immunity
R. Salehi-Rad, R. Lim, Yushen Du, Linh M. Tran +18 more
2023Journal for ImmunoTherapy of Cancer33 citations Open access
Semantic Scholar
OA15.04 Association Between KRAS/STK11/KEAP1 Mutations and Outcomes in POSEIDON: Durvalumab ± Tremelimumab + Chemotherapy in mNSCLC
S. Peters, B. Cho, A. Luft, J. Alatorre-alexander +16 more
2022Journal of Thoracic Oncology32 citations Open access
Semantic Scholar
Surgical results of the Lung Cancer Mutation Consortium 3 trial: A phase II multicenter single-arm study to investigate the efficacy and safety of atezolizumab as neoadjuvant therapy in patients with stages IB-select IIIB resectable non–small cell lung cancer
V. Rusch, A. Nicholas, G. Patterson, Salama N. Waqar +25 more
2022Journal of Thoracic and Cardiovascular Surgery30 citations Open access
Semantic Scholar
Consent document translation expense hinders inclusive clinical trial enrollment
M. Velez, Beth A. Glenn, M. Garcia-Jimenez, A. Cummings +15 more
2023Nature29 citations Open access
Semantic Scholar
973MO KEYNOTE-189 5-year update: First-line pembrolizumab (pembro) + pemetrexed (pem) and platinum vs placebo (pbo) + pem and platinum for metastatic nonsquamous NSCLC
M. Garassino, S. Gadgeel, G. Speranza, E. Felip +16 more
2022Annals of Oncology26 citations Open access
Semantic Scholar
Accelerated Hypofractionated Chemoradiation Followed by Stereotactic Ablative Radiotherapy Boost for Locally Advanced, Unresectable Non-Small Cell Lung Cancer: A Nonrandomized Controlled Trial.
Trudy C. Wu, E. Luterstein, B. Neilsen, J. Goldman +9 more
2024JAMA Oncology25 citations Open access
Semantic Scholar
Mocetinostat in Combination With Durvalumab for Patients With Advanced NSCLC: Results From a Phase I/II Study.
M. Johnson, J. Strauss, M. Patel, E. Garon +5 more
2023Clinical Lung Cancer24 citations
Semantic Scholar
RELAY, Ramucirumab Plus Erlotinib (RAM+ERL) in Untreated Metastatic EGFR-Mutant NSCLC (EGFR+ NSCLC): Association Between TP53 Status and Clinical Outcome.
M. Nishio, L. Paz-Ares, M. Reck, K. Nakagawa +6 more
2023Clinical Lung Cancer23 citations Open access
Semantic Scholar
Sacituzumab govitecan (SG) + pembrolizumab (pembro) in first-line (1L) metastatic non-small cell lung cancer (mNSCLC) with PD-L1 ≥ 50%: Cohort A of EVOKE-02.
Jyoti D. Patel, B. C. Cho, M. Cobo, Roxana Reyes Cabanillas +11 more
2024Journal of Clinical Oncology21 citations
Semantic Scholar
Safety and Efficacy Results from iSABR, a Phase I Study of Stereotactic Ablative Radiotherapy (SABR) in Combination with Durvalumab for Early-Stage Medically Inoperable Non-Small Cell Lung Cancer (NSCLC).
Trudy C. Wu, Annalise Stube, C. Felix, D. Oseguera +16 more
2023International Journal of Radiation Oncology, Biology, Physics21 citations
Semantic Scholar
Facets of Stigma, Self-Compassion, and Health-Related Adjustment to Lung Cancer: A Longitudinal Study
Timothy J. Williamson, E. Garon, Jenessa R. Shapiro, D. Chavira +2 more
2022Health Psychology20 citations Open access
Semantic Scholar
Bintrafusp alfa with cCRT followed by bintrafusp alfa versus placebo with cCRT followed by durvalumab in patients with unresectable stage III NSCLC: A phase 2 randomized study.
E. Vokes, Françoise Mornex, A. Sezer, Ying Cheng +16 more
2023Journal of Thoracic Oncology19 citations Open access
Semantic Scholar
Targeting EZH2 to overcome the resistance to immunotherapy in lung cancer.
D. Shin, Kevin B. Park, E. Garon, S. Dubinett
2022Seminars in Oncology19 citations Open access
Semantic Scholar
Detecting HLA loss of heterozygosity within a standard diagnostic sequencing workflow for prognostic and therapeutic opportunities
Ariane Lozac’hmeur, Tyler Danek, Qi-Di Yang, M. Rosasco +12 more
2024npj Precision Oncology17 citations Open access
Semantic Scholar
Ramucirumab plus erlotinib versus placebo plus erlotinib in previously untreated EGFR-mutated metastatic non-small-cell lung cancer (RELAY): exploratory analysis of next-generation sequencing results
E. Garon, M. Reck, K. Nishio, J. Heymach +9 more
2023ESMO Open16 citations Open access
Semantic Scholar
Clinical outcomes of ramucirumab plus docetaxel in the treatment of patients with non-small cell lung cancer after immunotherapy: a systematic literature review
E. Garon, C. Visseren-Grul, M. T. Rizzo, T. Puri +2 more
2023Frontiers in Oncology16 citations Open access
Semantic Scholar
43P MRTX-500: Phase II trial of sitravatinib (sitra) + nivolumab (nivo) in patients (pts) with non-squamous (NSQ) non-small cell lung cancer (NSCLC) progressing on or after prior checkpoint inhibitor (CPI) therapy
T. Leal, D. Berz, I. Rybkin, W. Iams +14 more
2022Annals of Oncology16 citations Open access
Semantic Scholar
Comparison of the tumor immune microenvironment and checkpoint blockade biomarkers between stage III and IV non-small cell lung cancer
Yin-Jie Gao, M. Stein, M. Kase, A. Cummings +4 more
2022Cancer Immunology and Immunotherapy16 citations Open access
Semantic Scholar
603O First clinical results from a phase I trial of PRT3789: A first-in-class intravenous SMARCA2 degrader, in patients with advanced solid tumors with a SMARCA4 mutation
R. Guo, A. Dowlati, I. Dagogo-Jack, J. Vibert +16 more
2024Annals of Oncology15 citations
Semantic Scholar
A Brief Report of Durvalumab With or Without Tremelimumab in Combination With Chemotherapy as First-Line Therapy for Metastatic Non-Small-Cell Lung Cancer: Outcomes by Tumor PD-L1 Expression in the Phase 3 POSEIDON Study.
E. Garon, B. C. Cho, Alexander V. Luft, J. Alatorre-alexander +16 more
2024Clinical Lung Cancer14 citations Open access
Semantic Scholar
Safety of pemetrexed plus platinum in combination with pembrolizumab for metastatic nonsquamous non-small cell lung cancer: A post hoc analysis of KEYNOTE-189.
E. Garon, J. Aerts, J. S. Kim, C. Muehlenbein +3 more
2021Lung Cancer12 citations Open access
Semantic Scholar
TRITON: Phase 3b study of tremelimumab (T) + durvalumab (D) vs pembrolizumab (P), in combination with chemotherapy (CT), in non-squamous (NSQ) metastatic NSCLC (mNSCLC) with STK11and/or KEAP1 and/or KRAS mutations.
F. Skoulidis, H. Borghaei, E. Garon, T. Leal +8 more
2024Journal of Clinical Oncology11 citations Open access
Semantic Scholar
Patient-reported outcomes in capmatinib-treated patients with METex14-mutated advanced NSCLC: Results from the GEOMETRY mono-1 study.
J. Wolf, E. Garon, H. Groen, D. S. Tan +8 more
2022European Journal of Cancer11 citations Open access
Semantic Scholar
Primary analysis from the phase 2 study of continuous talazoparib (TALA) plus intermittent low-dose temozolomide (TMZ) in patients with relapsed or refractory extensive-stage small cell lung cancer (ES-SCLC).
J. Goldman, A. Cummings, M. Mendenhall, M. Velez +10 more
2022Journal of Clinical Oncology11 citations
Semantic Scholar
cfTrack, a method of Exome-wide mutation analysis of cell-free DNA to simultaneously monitor the full spectrum of cancer treatment outcomes including MRD, recurrence, and evolution
Shuo Li, Wei-Hua Zeng, X. Ni, Yonggang Zhou +9 more
2022Clinical Cancer Research11 citations Open access
Semantic Scholar
Patient-reported outcomes with durvalumab, with or without tremelimumab, plus chemotherapy as first-line treatment for metastatic non-small-cell lung cancer (POSEIDON).
E. Garon, B. Cho, Alexander V. Luft, J. Alatorre-alexander +15 more
2023Lung Cancer10 citations Open access
Semantic Scholar
26P Capmatinib in treatment (Tx)-naive MET exon 14-mutated (METex14) advanced non-small cell lung Cancer (aNSCLC): Updated results from GEOMETRY mono-1
J. Wolf, E. Garon, H. Groen, D. Tan +5 more
2022Annals of Oncology10 citations Open access
Semantic Scholar
Sleep Disturbance as a Mediator of Lung Cancer Stigma on Psychological Distress and Physical Symptom Burden
Timothy J. Williamson, E. Garon, Michael R. Irwin, Alyssa K. Choi +2 more
2024Psychosomatic Medicine9 citations Open access
Semantic Scholar
Brief Report: Severe Pneumonitis After Combined Thoracic Radiotherapy and Osimertinib
Clayton P. Smith, M. Xiang, Stephanie Yoon, Alan Lee +6 more
2023JTO Clinical and Research Reports9 citations Open access
Semantic Scholar
Capmatinib plus osimertinib versus platinum-pemetrexed doublet chemotherapy as second-line therapy in patients with stage IIIb/IIIc or IV EGFR-mutant, T790M-negative NSCLC harboring MET amplification.
Yi-Long Wu, Ji-Youn Han, T. Kato, F. Barlesi +8 more
2022Journal of Clinical Oncology8 citations
Semantic Scholar
Mass cytometry reveals classical monocytes, NK cells and ICOS+ CD4+ T cells associated with pembrolizumab efficacy in lung cancer patients
P. Rochigneux, A. Lisberg, Alejandro J. Garcia, S. Granjeaud +14 more
2022Clinical Cancer Research7 citations Open access
Semantic Scholar
Tiragolumab Plus Atezolizumab and Chemotherapy for Advanced Nonsquamous Non–Small Cell Lung Cancer
Mark A. Socinski, R. Stahel, Dae Ho Lee, F. Cappuzzo +17 more
2026JAMA Oncology6 citations Open access
Semantic Scholar
Phase 1 trial safety and efficacy of ragistomig, a bispecific antibody targeting PD-L1 and 4-1BB, in advanced solid tumors.
G. Falchook, Patricia M. LoRusso, J. Goldman, A. El-Khoueiry +15 more
2024Journal of Clinical Oncology6 citations
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

E. Felip×7
Invite
E. Felip — researcher profile on SciRah
M. Reck×7
Invite
M. Reck — researcher profile on SciRah
S. Gadgeel×6
Invite
S. Gadgeel — researcher profile on SciRah
A. Lisberg×6
Invite
A. Lisberg — researcher profile on SciRah

×6

Invite

S. Dubinett — researcher profile on SciRah

Invite

L. Paz-Ares — researcher profile on SciRah

Invite

J. Goldman — researcher profile on SciRah

J. Alatorre-alexander×5

Invite

J. Alatorre-alexander — researcher profile on SciRah

Invite

R. Hui — researcher profile on SciRah

D. Rodríguez-Abreu×4

Invite

D. Rodríguez-Abreu — researcher profile on SciRah

Invite

M. Johnson — researcher profile on SciRah

Invite

G. Ursol — researcher profile on SciRah